Divozilimab in neuromyelitis optica spectrum disorders: Evidence-based consensus of Russian committees of experts and clinical potential
Rattachement africain : ru, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Neuromyelitis optica spectrum disorders (NMOSD) are a group of inflammatory diseases of the central nervous system. B-lymphocytes play leading role in their pathogenesis in most cases. СD20 surface antigen is one of the B-lymphocytes makers. There is extensive world experience with chimeric monoclonal anti-CD20 antibody rituximab off-label using for NMOSD exacerbations prevention. It has been included in published international and Russian algorithms for NMOSD treatment along with other approved medications. Divozilimab is recombinant humanized anti-CD20 monoclonal antibody with a modified glycosylation pattern of Fc-fragment which is approved in Russian Federation for the treatment of multiple sclerosis, systemic scleroderma and also for NMOSD (September 2025). The publication is intended to present the results of the Russian Expert Councils work in September 2025 and February 2026. According to the analysis of publications on anti-CD20 NMOSD therapy, the 6-month results of divozilimab study BCD-132-6/AQUARELLE (NCT05730699) and data of additional subanalysis experts agreed the profiles of NMOSD patients for divozilimab therapy, time to full therapeutic effect and monitoring plan during treatment with divozilimab. Experts supplemented the algorithm for initial prescription and switching of medications for prevention of NMOSD attacks in patients with AQP4-IgG aged 18 years and older, agreed on the algorithm for the administration of medications for prevention of NMOSD attack in patients without AQP4-IgG aged 18 years and older, determined positions of divozilimab in both algorithms. According to experts opinion divozilimab appears as promising treatment option in NMOSD. Analysis of divozilimab effectiveness and safety long-term results in BCD-132-6/AQUARELLE study and real-world practice will be important steps toward clarifying and potentially extending patient profiles.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Divozilimab in neuromyelitis optica spectrum disorders: Evidence-based consensus of Russian committees of experts and clinical potential
- Date Crossref
- 14/09/2026
- Éditeur
- Remedium, Ltd.
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
First Pavlov State Medical University of St. Petersburg pays non établi dans la noticeUniversité ou école supérieure
-
Samara State Medical University pays non établi dans la noticeUniversité ou école supérieure
-
City Clinical Hospital No 31 pays non établi dans la noticeÉtablissement de santé
-
Novosibirsk State Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Krasnoyarsk Regional Clinical Hospital pays non établi dans la noticeÉtablissement de santé
-
Institute of the Human Brain pays non établi dans la noticeStructure de recherche
-
City Clinical Hospital pays non établi dans la noticeÉtablissement de santé
-
Municipal Autonomous Healthcare Institution pays non établi dans la noticeÉtablissement de santé
-
Samara Regional Clinical Hospital named after V.D. Seredavina pays non établi dans la noticeÉtablissement de santé
-
Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky pays non établi dans la noticeÉtablissement de santé
-
Regional Clinical Research pays non établi dans la noticeStructure de recherche
-
City Clinical Hospital No. 2 pays non établi dans la noticeÉtablissement de santé
First Pavlov State Medical University of St. Petersburg, Samara State Medical University et City Clinical Hospital No 31, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.